Payment overview · 2025
General Payments
$207.25
9 reported records · 8 companies
Healthcare provider profile · identity verified
John Westan Meyer, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SARASOTA, FL · NPI 1801828041
Verified facts
What the public records show
CMS Open Payments records show John Westan Meyer, MD received $207.25 in general payments during 2025 across 9 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $44.36 | 21.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.85 | 16.8% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $27.86 | 13.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.18 | 12.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.78 | 10.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.46 | 9.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.39 | 8.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.37 | 6.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $207.25 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $44.36 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $34.85 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $27.86 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $26.18 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
171 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 455 | 134 |
| Alprazolam | Alprazolam | 443 | 92 |
| Losartan Potassium | Losartan Potassium | 399 | 126 |
| Amlodipine Besylate | Amlodipine Besylate | 398 | 121 |
| Atorvastatin Calcium | Atorvastatin Calcium | 397 | 125 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 362 | 130 |
| Lisinopril | Lisinopril | 360 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 358 | 124 |
| Metformin Hcl | Metformin Hcl | 325 | 118 |
| Prednisone | Prednisone | 291 | 201 |
| Omeprazole | Omeprazole | 278 | 84 |
| Azithromycin | Azithromycin | 259 | 218 |
| Tramadol Hcl | Tramadol Hcl | 235 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 195 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 190 | 72 |
| Gabapentin | Gabapentin | 181 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 81 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 174 | 43 |
| Trazodone Hcl | Trazodone Hcl | 172 | 62 |
| Zolpidem Tartrate | Zolpidem Tartrate | 172 | 45 |
| Ozempic | Semaglutide | 171 | 37 |
| Valsartan | Valsartan | 146 | 56 |
| Meloxicam | Meloxicam | 134 | 72 |
| Eliquis | Apixaban | 133 | 37 |
| Labetalol Hcl | Labetalol Hcl | 128 | 38 |
| Fenofibrate | Fenofibrate Nanocrystallized | 124 | 45 |
| Dexamethasone | Dexamethasone | 120 | 106 |
| Simvastatin | Simvastatin | 116 | 36 |
| Cephalexin | Cephalexin | 115 | 97 |
| Alendronate Sodium | Alendronate Sodium | 111 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 33 |
| Allopurinol | Allopurinol | 103 | 31 |
| Carvedilol | Carvedilol | 93 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 92 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 28 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 86 | 70 |
| Sertraline Hcl | Sertraline Hcl | 80 | 24 |
| Finasteride | Finasteride | 77 | 24 |
| Glimepiride | Glimepiride | 74 | 27 |
| Celecoxib | Celecoxib | 73 | 31 |
| Furosemide | Furosemide | 72 | 30 |
| Methylprednisolone | Methylprednisolone | 71 | 64 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 45 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 20 |
| Clonazepam | Clonazepam | 68 | 14 |
| Diazepam | Diazepam | 67 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 18 |
| Ondansetron Odt | Ondansetron | 63 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 26 |
| Synthroid | Levothyroxine Sodium | 62 | 16 |
| Lorazepam | Lorazepam | 60 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 48 |
| Ezetimibe | Ezetimibe | 59 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 38 |
| Mirtazapine | Mirtazapine | 58 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 19 |
| Atenolol | Atenolol | 54 | 22 |
| Fenofibrate | Fenofibrate | 53 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 14 |
| Potassium Chloride | Potassium Chloride | 49 | 25 |
| Amoxicillin | Amoxicillin | 48 | 41 |
| Estradiol | Estradiol | 47 | 14 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 46 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 40 | 17 |
| Topiramate | Topiramate | 40 | 12 |
| Bupropion Xl | Bupropion Hcl | 38 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 11 |
| Buspirone Hcl | Buspirone Hcl | 35 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 35 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | 21 |
| Azelastine Hcl | Azelastine Hcl | 31 | 22 |
| Mupirocin | Mupirocin | 31 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 27 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 29 |
| Spironolactone | Spironolactone | 30 | suppressed |
| Minoxidil | Minoxidil | 28 | 12 |
| Propranolol Hcl | Propranolol Hcl | 28 | 11 |
| Telmisartan | Telmisartan | 28 | suppressed |
| Temazepam | Temazepam | 28 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 16 |
| Valacyclovir | Valacyclovir Hcl | 26 | 16 |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 16 |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | 17 |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Modafinil | Modafinil | 17 | suppressed |
| Nystatin | Nystatin | 17 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Erythromycin | Erythromycin Base | 12 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $207.25 · 9 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | AIRSUPRA, CAPLYTA, JATENZO, KISUNLA, OTEZLA, REPATHA, The Cologuard Plus Collection Kit, Wegovy, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error